Latest Psilocybin Microdosing Study, Powered by Quantified
VANCOUVER, British Columbia, July 11. 2, 2022 (GLOBE NEWSWIRE) — The second manuscript of the world’s largest microdosing study, facilitated by Quantified Citizen (QC) and officially titled “Psilocybin Microdosers Demonstrate Greater Observed Improvements in Mood and Mental Health in one month compared to controls without microdosing,” was published by Nature: scientific reports. The document is accessible here.
The article shows how microdosing psilocybin is associated with general improvements in mood and mental health. Additionally, a finding specific to people over the age of 55 indicated that microdosing was associated with greater improvements in psychomotor performance compared to non-microdosing. Additionally, adults over the age of 55 showed an even greater improvement in psychomotor performance when psilocybin is stacked with lion’s mane and niacin (“Stamets Stack”) compared to psilocybin alone. These findings may help inform the design of human clinical trials involving psychedelics.
A common criticism of observational studies of this type is that they are uncontrolled and unable to distinguish placebo effects from those related to the true pharmacological effects of psychedelics. The purpose of observational research is to observe behaviors as they occur naturally in the world and to draw conclusions without interfering with these natural practices. Although an expectation effect cannot be ruled out for depression, anxiety, and stress, reports of subjective benefits are supplemented by improvements in the study’s psychomotor task (the Finger Tap Task), which which adds robustness to the results.
“The results of the tap test are interesting. While a placebo in this type of observational study is not appropriate, the results of the tap test with a microdosage combining psilocybin, niacin, and lion’s mane above from baseline, and compared to psilocybin taken with any other combination, stand out as a strong signal of importance for psychomotor performance. The QC app was designed for such a purpose: to find improvements that can further inform the design of clinical studies – with double-blind placebo controls. It’s hard to imagine expectation would be selective in using this stack in improving the tap test in an older population. We’re thrilled to test this clinically,” notes Paul Stamets.
Here are some new ideas from this new publication:
1. From baseline to month 1, microdosers consistently report greater decreases in mental health-related symptoms than non-microdosers.
2. Adults over 55 who microdosed with psilocybin mushrooms in the Stamets Stack showed the largest increases (about 40%) in total taps after about a month compared to non-microdosers and to those who microdosed psilocybin alone.
The study, informally called Microdose.me, has more than 19,000 participants from around the world and has been presented at numerous conferences, including SXSW, Summit LA, TED and Life Itself. The study was conducted in partnership with the University of British Columbia, Maastricht University, Paul Stamets and Dr. Pamela Kryskow, among others.
“I am proud of the ongoing efforts to improve the study design through feedback from our participants, supporters and other scientists. Together with fellow citizens and researchers, we are developing versions of the study that will be used to generate discoveries related to psychedelic microdosing for years to come,” shared Quantified Citizen Director of Research Maggie Kiraga.
The study team is currently recruiting users and non-users of psychedelics for the second version of the study, which will contain new active tasks and questionnaires that will examine connection to nature, psychedelic craving and mindfulness, among others.
Quantified Citizen is a health research app based on citizen science. It has a growing library of studies on interventions, techniques and emerging trends. The app is available on iOS and Android.
To fuel growth and the development of new survey capabilities, Quantified Citizen is currently in the process of increasing its Series A funding round.
Nikki Paqueo, Product Marketing Manager
[email protected], +1-604-800-2911
Eesmyal Santos-Brault, co-founder and CEO
[email protected], +1-604-800-2911
Image 1: Exciting results from the latest psilocybin microdosing study
This content was posted through the press release distribution service on Newswire.com.
Exciting results from the latest psilocybin microdosing study